“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.